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Sialidases and trans-sialidases play important roles in the life cycles of various
microorganisms. These enzymes can serve nutritional purposes, act as virulence
factors or mediate cellular interactions (cell evasion and invasion). In the case
of the protozoan parasite Trypanosoma vivax, trans-sialidase activity has been
suggested to be involved in infection-associated anaemia, which is the major
pathology in the disease nagana. The physiological role of trypanosomal trans-
sialidases in host–parasite interaction as well as their structures remain obscure.
Here, the production, purification and crystallization of a recombinant version
of T. vivax trans-sialidase 1 (rTvTS1) are described. The obtained rTvTS1
crystals diffracted to a resolution of 2.5 A˚ and belonged to the orthorhombic
space group P212121, with unit-cell parameters a = 57.3, b = 78.4, c = 209.0 A˚.
1. Introduction
Sialic acids (SA) are negatively charged sugars that are
present in a multitude of complex carbohydrates on the
surfaces of mammalian cells, including red blood cells (RBCs;
Chen & Varki, 2010). These sugars play important roles in a
myriad of biological processes, such as cell adhesion, inter-
cellular communication and self-recognition processes, regu-
lation of immune responses and apoptosis (Engstler et al.,
1993; Pshezhetsky & Ashmarina, 2013). Interestingly, SA are
also key components for host–pathogen interactions. Like
the cells of the animal host, pathogens and commensals can
decorate their surfaces with SA (Varki & Gagneux, 2012). This
helps pathogens to modulate the host’s immune system, to
avoid immune recognition and to invade host cells (Stafford et
al., 2012; Montagna et al., 2006; Schenkman et al., 1991; Blom-
Potar et al., 2010; Muia´ et al., 2010; Schauer & Kamerling,
2011). In addition, some pathogens require host-derived SA
for nutritional requirements. While mammals can synthesize
SA de novo via a complex biochemical pathway, it seems that
many host-associated viral, fungal, bacterial and parasitic
pathogens partially or completely lack the genes necessary for
SA biosynthesis. Instead, these pathogens have evolved to
scavenge SA from their host organism.
One of the most common strategies that SA auxotroph
pathogens employ to procure host SA is through the action of
pathogen-encoded sialidases and trans-sialidases. Sialidases
are able to cleave off SA from host sialyl donors and release
the product into the surrounding environment. Even though
the overall sequences of sialidases are divergent, a so-called
‘sialidase motif’ and the active-site residues are highly
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conserved. Enzymatic removal of SA from the host cells by
means of a pathogen’s sialidase(s) results in exposure of the
underlying glycans, thus perturbing natural self-recognition
phenomena and potentially increasing inflammatory
responses by exposing desialylated danger-associated mole-
cular patterns (DAMPS; Chen & Nun˜ez, 2010; Varki, 2011).
Moreover, diminished SA surface levels reduce the surface
hydrophilicity of host cells, decrease charge repulsion between
host cells and disturb the endogenous receptor interactions.
The damaging effects of SA disturbances could explain why
active host sialidases are not present in extracellular fluids.
The closely related trans-sialidases are also used by a subset of
pathogens to scavenge SA from the host organism. Trans-
sialidase enzymes share the ‘sialidase motif’ but have a distinct
mode of action. The members of this enzyme class use host
glycoconjugates as sialyl donors, but transfer the SA to
parasite acceptor molecules rather than water. Coinciding
with their highly conserved sialidase-like active site, it has
been shown that trans-sialidases exhibit residual sialidase
activity in the absence of the appropriate acceptor (Cross &
Takle, 1993; Harrison et al., 2001; Gbem et al., 2013). In
contrast to sialidases, it is interesting to note that the structural
and mechanistic features of trans-sialidases remain under-
studied, as only a handful of these enzymes have been char-
acterized (Cheng et al., 2008, 2009; Gut et al., 2008; Newstead
et al., 2004).
The members of the Trypanosoma genus are protozoan
parasites that infect and can cause disease in cattle and
humans, mainly in Africa and South America. In the case of
cattle infection, the induced disease is called nagana, and is
caused mainly by T. congolense and T. vivax, and to a lesser
extent by T. brucei. To successfully complete their life cycle,
the African cattle-infecting trypanosomes (T. brucei and
T. congolense) require alternate passages through insects of
the Glossina species and a mammalian host. In contrast,
T. vivax does not depend on the insect-vector stage to
complete its life cycle. Instead, T. vivax has evolved to employ
any species of biting fly for mechanical transmission into a new
host. This has allowed T. vivax to spread further to South
America through cattle transport. Given the severity of the
consequences of trypanosome infection in cattle (weight loss,
diminished milk production and death; Taylor, 1998) and the
inability to treat and/or clear the infection (Barrett & Fair-
lamb, 1999; Taylor & Mertens, 1999; La Greca & Magez, 2011),
nagana causes severe economic losses. Like many other host-
associated pathogens, trypanosomes lack genes for SA
biosynthesis and scavenge SA from their host by employing
sialidases and trans-sialidases. In some trypanosomes (for
example, the pathogenic T. brucei and the nonpathogenic
T. rangeli), the use of their (trans-)sialidases is restricted to
the insect stage and is believed to provide protection of
the parasite during its journey through the insect midgut
(Montagna et al., 2002). In other cases, trypanosomal (trans-)
sialidases are produced in the so-called ‘bloodstream form’
(i.e. the mammalian host stage) and their actions are thought
to be directly correlated with the induced pathology in the
infected mammalian host (Schenkman et al., 1991; Nok &
Balogun, 2003; Buratai et al., 2006). In T. cruzi, the only
intracellular trypanosome, it has been shown that its trans-
sialidases play a role in host-cell invasion, parasite virulence
and immune suppression (Schenkman et al., 1992; Buschiazzo
et al., 2002; Jacobs et al., 2010; Giorgi & de Lederkremer,
2011). In T. vivax infections, trans-sialidase activity has been
proposed to be linked to the typically observed severe
anaemia (Bratosin et al., 1998; Buratai et al., 2006; Guegan et
al., 2013). Hence, for disease-associated trypanosomal trans-
sialidases, unravelling their structure–function relationship
might yield insights into the molecular mechanisms behind the
onset of trypanosomosis-induced pathologies.
In this article, we describe the production, purification,
crystallization conditions and preliminary X-ray analysis of
the recombinant T. vivax trans-sialidase 1 (rTvTS1). Studying
this enzyme is of interest because of its low sequence identity
to other trypanosomal sialidases and trans-sialidases with
known structures (30.1% to that from T. rangeli and 24.9%
to that from T. cruzi), its distinct biological function and its
possible medical relevance (Buschiazzo et al., 2002; Amaya et
al., 2003, 2004). It is expected that crystal structure determi-
nation of rTvTS1 will not only contribute to increasing the
knowledge of the understudied class of trans-sialidase
enzymes but will also provide insights into its biological role in
T. vivax infections.
2. Materials and methods
2.1. Construction of the expression vectors and transfection
in Pichia pastoris
Three expression vectors (named pPpT4_S_TvTS1,
pPpT4_S_TvTS2 and pPpT4_S_TvTS3) were constructed
and respectively encode three representative trans-sialidase
(TS) variants from T. vivax Y486 (TvTS1, GenBank ID
CAEX01006974; TvTS3, GenBank ID CAEX01004555;
TvTS4, GenBank ID HE573024). The native coding
molecular parasitology
578 Haynes et al.  Trans-sialidase from T. vivax Acta Cryst. (2015). F71, 577–585
Figure 1
Schematic overview of the synthesized rTvTS1-encoding gene. The catalytic and lectin-like domains are indicated by orange and green boxes,
respectively. The C-terminal hexahistidine tag is displayed as a blue box and the grey box shows a domain of unknown function. The AvrII and NotI
restriction sites necessary for subcloning are also indicated (red boxes). The resulting protein product has a length of 876 residues and a theoretical
molecular mass of 97.6 kDa.
sequences were engineered to facilitate protein production in
and secretion by the methylotrophic yeast P. pastoris (Fig. 1).
Firstly, the predicted signal peptides of the trans-sialidases
(except for TvTS3, which does not contain such a leader
peptide) were removed. Secondly, AvrII and NotI restriction
sites were introduced for ligation into the desired expression
vector (pPpT4_S, a modified version of the pPIC9 vector;
Laroy & Contreras, 2000). In order to detect and purify the
target proteins, they were equipped with a C-terminal hexa-
histidine tag. The engineered genes were codon-optimized and
synthesized by GenScript.
The three synthetic sequences were delivered in a pUC57
vector (Ampr) and were multiplied by transformation in
Escherichia coli WK6 [(lac-proAB), galE, strA/F0 lacIq,
lacZM15, proA+B+; Zell & Fritz, 1987]. Using a GenePulser
(Bio-Rad), electroporation was performed according to the
manufacturer’s instructions for bacteria: 1.8 kV, a capacitance
of 25 mF and a resistance of 200 . The transformed cells were
selected on LB plates containing 100 mg ml1 ampicillin and
2% glucose. Next, clones containing the insert [as confirmed
by colony PCR using TvTS-generated primers: rTvTS1_FW
(50-ACTCGTGGATACTGGACCTT-30), rTvTS3_FW (50-TG-
CGAGAGGTTACTGGACTT-30), rTvTS4_FW (50-ACGTG-
GAAGACCGAAGTTATT-30), rTvTS1_RV (50-TGGCCAG-
AACAGTCCATGAT-30), rTvTS3_RV (50-AATGCACTCC-
GCCTGAATCG-30) and rTvTS4_RV (50-TTCGTCAGTCA-
GACGGATTC-30)] were expanded overnight in 5 ml LB
medium supplemented with 2% glucose and 100 mg ml1
ampicillin (shaking at 200 rev min1 at 310 K). The plasmids
were extracted using a commercial kit (Invitrogen Plasmid
miniPrep) according to the manufacturer’s instructions. After
digestion with Fermentas FastDigest AvrII and NotI restric-
tion enzymes, the TvTS DNA inserts were incorporated by the
use of Fermentas T4 DNA ligase into the linearized pPpT4_S
vector Zeor and introduced into E. coli DH5 electro-
competent cells (Invitrogen). The transformed cells were then
selected on LB plates containing 50 mg ml1 Zeocin (Invi-
trogen) according to the manufacturer’s instructions. Colony
PCR was performed using the commercially available AOX1
forward (50-GACTGGTTCCAATTGACAAGC-30) and
reverse (50-GGCAAATGGCATTCTGACATCCT-30) primers
from Invitrogen. pPpT4_S clones containing the TvTS inserts
were amplified overnight in LB medium supplemented with
2% glucose and 50 mg ml1 Zeocin (shaking at 200 rev min1
at 310 K) and the plasmids were extracted as described above.
In order to confirm the correctness of the inserted sequences,
the plasmids were sent for sequencing. Plasmids of each
variant were further amplified and purified (as described
above) in order to yield high amounts for transfection into the
yeast P. pastoris. 10 mg of each pPpT4_S_TvTS vector was
digested with a threefold excess of New England Biolabs
(NEB) PmeI restriction enzyme for 3 h in a water bath at
310 K. The linearized vector was purified according to the
manufacturer’s instructions using an NEB NucleoSpin Extract
II Kit (eluted in 20 ml ultrapure water). Complete linearization
of the vector was assessed by loading the digestion mixture
onto an agarose gel.
Next, P. pastoris cells were made electrocompetent and
transfected as described by Jacobs et al. (2009). A fresh
P. pastoris colony was used to inoculate 5 ml yeast extract
peptone dextrose [YPD; 1% yeast extract, 2% peptone, 2%
dextrose (glucose)] medium and was grown overnight at 301 K
with shaking at 250 rev min1. The next morning, the pre-
culture was used to inoculate baffled shake flasks containing
250 ml YPD medium. The cells were allowed to grow over-
night at 301 K with shaking at 250 rev min1 until the culture
reached an OD600 nm of 1.5 (i.e. approximately 7.5 
107 cells ml1). The cells were then harvested by centrifuga-
tion for 5 min [1500g (3000 rev min1 in a F10S-6x500y rotor)]
at 277 K. The supernatant was removed and the cells were
resuspended in lithium acetate/DTT solution (100 mM lithium
acetate, 10 mM DTT, 0.6 M sorbitol, 10 mM Tris–HCl pH 7.5)
at 108 cells ml1 and incubated for 30 min at 298 K with gentle
shaking at 100 rev min1. The centrifugation step was repe-
ated as described above, the supernatant was removed and the
cells were resuspended in 1.5 ml ice-cold 1 M sorbitol per 5 
108 cells. From this point on, the cells were kept on ice. The
sorbitol wash described above was repeated two times. The
cells were harvested by centrifugation for 5 min [1800g
(2730 rev min1 in a A-4-81 rotor)] at 277 K and the super-
natant was removed. The cells were resuspended in 1 M ice-
cold sorbitol to obtain a final concentration of 1010 cells ml1.
Fresh electrocompetent P. pastoris cells (80 ml) were then
incubated with 300 ng linearized plasmid DNA for 5 min at
277 K in a pre-cooled Bio-Rad GenePulser electroporation
cuvette (0.2 cm). Using a GenePulser (Bio-Rad), the cells
were pulsed using the manufacturer’s parameters for yeast:
1.5 kV, a capacitance of 25 mF, an extended capacitance of
125 mF and a resistance of 200 . 1 ml ice-cold 1 M sorbitol
was added directly after pulsing the cells. The transfected cells
were transferred into a sterile 15 ml tube and incubated
without shaking at 303 K for 1–2 h. Finally, 10, 50 and 200 ml
of cell suspension were plated on YPD plates containing
100 mg ml1 Zeocin and incubated for 2–3 d at 303 K until
colonies appeared.
2.2. Protein production and purification
Small-scale expression clones containing the different
rTvTS inserts from the YPD plates were inoculated in 2 ml
buffered glycerol-complex medium (BMGY; 1% yeast extract,
2% peptone, 100 mM potasium phosphate pH 7, 1.34% yeast
nitrogen base, 1% glycerol) in 24-well plates. After 24 h,
the cells were collected and resuspended in 2 ml buffered
methanol-complex medium (BMMY; 1% yeast extract, 2%
peptone, 100 mM potassium phosphate pH 7, 1.34% yeast
nitrogen base, 1% methanol). Methanol-induced expression
was allowed for 48 h, with the addition of 0.5% methanol after
12 h. The plates were then centrifuged for 7 min [1600g
(3120 rev min1 in an A-2-DWP swing bucket rotor)] at 277 K.
The collected yeast supernatants were screened for protein
production using dot blotting. Detection of TvTS protein was
performed using mouse anti-HIS (Sigma–Aldrich, catalogue
No. H1029) followed by goat anti-mouse HRP (Sigma–
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Aldrich, catalogue No. A4416). In order to optimize produc-
tion yields, the constructs were transfected into three different
P. pastoris strains (YA215, YA284 and YA550). Furthermore,
the additives HisHAC or BHH were added to the culture
medium to optimize growth and protein-production condi-
tions. The Y215 strain (+ HisHAC) was selected as the best
producer based on SDS–PAGE supernatant profiles.
For the reasons discussed in x3, large-scale production was
only performed for rTvTS1. Here, 250 ml shaking flasks with
200 ml BMGY medium were inoculated with 1 ml cell pre-
cultures grown overnight in 5 ml BMGY in 50 ml Falcon tubes.
After 48 h shaking at 250 rev min1 and 303 K (OD600 nm of
around 15), cells were collected by centrifugation for 7 min
[3000g (4200 rev min1 in a F10S-6x500y rotor)] at 303 K and
resuspended in 200 ml BMMY. Methanol-induced expression
was allowed for 48 h at 250 rev min1 and 303 K with addition
of 1% methanol every 12 h. Cells were then collected by
centrifugation for 7 min [3000g (4200 rev min1 in a F10S-
6x500y rotor)] at 277 K and the supernatant was collected.
Finally, in order to proceed to the purification step, the
supernatant was desalted by adding a 100-fold dilution of
glutathione solution (200 mM MgCl2 + 10 mg ml
1 gluta-
thione), a 50-fold dilution of glutathione solution containing
1 M imidazole and adjusting the pH to 7.5 with 1 M NaOH.
After precipitation of the salts, the supernatant was collected
and filter-sterilized.
Ni–NTA chelating beads (HisPur Ni–NTA resin, Thermo
Scientific) were used to capture and purify the recombinant
protein from the yeast supernatant. Small-scale purification
was performed in the same way for all TvTS variants. A PD-10
column (GE Healthcare) was packed with 2 ml Ni–NTA beads
and equilibrated with phosphate-buffered saline (PBS) pH 7.0
over five column volumes. Next, the desalted supernatant was
loaded onto the column followed by a wash with PBS pH 7.0
over ten column volumes. Finally, the rTvTS was eluted using
PBS pH 7.5 containing 500 mM imidazole. All of the above
steps were performed at room temperature, and gravitational
force was employed to drain the solutions through the column.
Large-scale purification was only performed for rTvTS1. A
PD-20 column (GE Healthcare) was packed with Ni–NTA
beads and connected to a peristaltic pump (Watson 101U/R).
The column was extensively equilibrated with PBS pH 7.0 at
5 ml min1. The desalted supernatant was then passed through
the column at 1.5 ml min1. The column was washed with PBS
pH 7.0 containing 10 mM imidazole over two column volumes
at 2 ml min1. Finally, the rTvTS was eluted using PBS pH 7.5
containing 250 mM imidazole. All of the above steps were
performed at 277 K. For both small-scale and large-scale
purification, the imidazole was removed from the eluate by
overnight dialysis (Spectra/Por 1 MWCO 6–8 kDa) in 20 mM
MES, 10 mM NaCl, 5% glycerol pH 6.0 at 277 K.
For the deglycosylation of rTvTS, 21 mg rTvTS1 in 20 mM
MES pH 6.0, 10 mM NaCl, 5% glycerol was first concentrated
to 7 mg ml1 using a Vivaspin 20 MWCO (PES) 5000 and
incubated overnight with 50 000 U endoglycosidase Hf
(EndoHf; NEB) at 277 K on a table-top shaker at
100 rev min1. The sample was then centrifuged for 2 min
[20 000g (14 000 rev min1 in a F45-30-11 rotor)] at 277 K to
pellet the carbohydrate residues. Using the predicted differ-
ence in pI between EndoHf and rTvTS1 (pI of 5.5 and 9.0,
respectively), the EndoHf was separated from the deglycosy-
lated rTvTS1 protein by ion exchange. After equilibration
of the cation-exchange column (5 ml HiTrap SP FF, GE
Healthcare) in 20 mM MES pH 6.0, 10 mM NaCl, 5% glycerol,
the solution containing deglycosylated rTvTS1 and EndoHf
was loaded onto the column. A NaCl gradient (from 10 mM to
1 M) was performed, in which the positively charged rTvTS1
protein eluted around 290 mM NaCl while the (close to)
neutrally charged EndoHf eluted in the flowthrough. After
purification, the deglycosylated product was concentrated (as
described above) and the salt concentration of the buffer was
decreased to 150 mM.
2.3. Activity assays
The following activity assays were performed at several
stages throughout the production and purification steps to
measure the biological activity of all produced and purified
rTvTS constructs. Both sialidase and trans-sialidase activity
assays were monitored via product release of the fluorophore
4-methylumbelliferone (MU). In both assays, enzyme activity
was measured using a fluorometer (FluoStar Optima, BMG
Labtech, Germany) with excitation at 365 nm and emission at
450 nm. Fluorescence was measured every minute for 2 h at
310 K. Blank values (empty-vector supernatant or buffer with
substrate) were systematically subtracted. Fluorescence was
calibrated as the amount of product formed by a previously
defined MU standard curve. Recombinant T. cruzi trans-
sialidase (rTcTS) was used as a positive control.
In the sialidase activity assay, 500 mM 20-(4-methylumbelli-
feryl)--d-N-acetylneuraminic acid (Mu-Neu5Ac) substrate
and 0.2% bovine serum albumin were combined with the
rTvTS protein sample in a final volume of 100 ml. Upon
sialidase activity, the substrate is cleaved into -d-N-acetyl-
neuraminic acid (a sialic acid) and the MU fluorophore. In the
trans-sialidase activity assay, 25 ml sample was incubated with
1 mM 2,3-sialyllactose (2,3-SL), representing the donor,
and 2 mM MU--d-galactopyranoside (MU-Gal), repre-
senting the acceptor, in a final volume of 50 ml at 310 K for 2 h.
Upon TS activity, the sialyl group from the donor is trans-
ferred to the acceptor MU-Gal. The reaction was stopped by
adding 1 ml ice-cold water. The solution was then incubated
with 300 ml Q Sepharose Fast Flow resin (Sigma–Aldrich). The
resin was activated prior to the experiment by overnight
incubation in 1 M sodium acetate and washed three times
with ice-cold water [centrifugation for 1 min at 2000g
(3150 rev min1 in an A-4-81 rotor) at 277 K]. The mixture
was homogenized by inversion and centrifuged for 1 min
[2000g (4340 rev min1 in an F-45-30-11 rotor)] at 277 K and
washed three times with ice-cold water. The negatively
charged sialyl residues were thus captured by the anion-
exchange Q Sepharose beads (both the remaining donor
and the sialylated acceptor). The sialylated product (and
remaining donor) was eluted by mixing the resin with 700 ml
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Figure 2
T. vivax TvTS1 contains the conserved ‘sialidase motif’. The top panel displays a schematic representation of an alignment between sialidases and trans-
sialidases from various organisms (from top to bottom): S. typhimurium sialidase (UniProt P29768), P. distasonis sialidase (UniProt A6LG40),
A. fumigatus sialidase (UniProt Q4WQS0), H. sapiens sialidase (UniProt Q9Y3R4), T. cruzi trans-sialidase (UniProt Q26964), T. rangeli sialidase
(UniProt Q27064) and T. vivax TvTS1 (UniProt F9WU40). All sequences contain the conserved sialidase residues (black bars) and the ‘sialidase motif’
(FRxP and SxDxGxT-W/x, indicated by a star and a rectangle, respectively). The catalytic domains, lectin-like domains and domains of unknown
function are displayed as orange, green and grey boxes, respectively. The immunogenic SAPA repeats of T. cruzi trans-sialidase are indicated by the
brown box. The alignment was generated using the MAFFT algorithm (Katoh et al., 2002) within the Geneious Pro program suite (Biomatters Ltd). The
bottom panel represents a POODLE-L (Hirose et al., 2007) analysis of the TvTS1 sequence. Scores above 0.5 indicate disorder/flexibility and regions
with predicted disorder are highlighted by their amino-acid numbers. The scissors indicate the proteolytic cuts generated during protein production and
the four resulting products observed during SDS–PAGE are schematically depicted below the POODLE-L analysis.
1 N HCl. The eluate was collected by centrifugation for 2 min
[2000g (4340 rev min1 in an F-45-30-11 rotor)] at 277 K. In
order to release the MU fluorophore from the sialylated
acceptor for fluorescence measurements, the solution was
hydrolysed at 368 K for 45 min and then allowed to thaw on
ice. Finally, the sample was neutralized by first adding 290 ml
2 N NaOH and then 300 ml 1 M Tris–glycine pH 10.0.
2.4. Analytical gel filtration
Analytical gel-filtration experiments were performed on an
A¨KTAexplorer platform (GE Healthcare) using a Superdex
200 HR 16/60 column (GE Healthcare) to determine the size
and molecular mass of the deglycosylated rTvTS1. The column
was pre-equilibrated using running buffer (20 mM MES pH
6.0, 150 mM NaCl, 5% glycerol) for at least one column
volume. A 500 ml sample at a concentration of 6 mg ml1 was
injected using running buffer at a flow rate of 1.5 ml min1. To
determine the molecular masses and the hydrodynamic radii
of the proteins (Uversky, 1993), the column was calibrated
using molecular-mass standards from Bio-Rad.
2.5. Crystallization, data collection and data processing
Crystallization conditions for purified, deglycosylated
rTvTS1 were manually screened using the sitting-drop vapour-
diffusion method in 96-well plates (MRC 2 well crystallization
plates, Swissci) with drops consisting of 1 ml rTvTS1
(10 mg ml1) and 1 ml reservoir solution equilibrated against
100 ml reservoir solution. Commercial screens from Molecular
Dimensions (ProPlex and PACT premier), Hampton Research
(Grid Screen Salt HT) and Jena Bioscience (JBScreen Basic)
were used for initial screening. All plates were incubated at
293 K. The C-terminal hexahistidine tag was retained for
crystallization.
Of the 384 conditions screened, four produced promising
hits (with the appearance of microcrystals) after incubation
for 7–14 d. All hits were from the PACT premier screen:
conditions A6 [100 mM SPG buffer pH 9.0, 25%(w/v) PEG
1500], A7 [200 mM sodium chloride, 100 mM sodium acetate
pH 5.0, 20%(w/v) PEG 6000], A8 [200 mM ammonium
chloride, 100 mM sodium acetate pH 5.0, 20%(w/v) PEG
6000] and B9 [200 mM lithium chloride, 100 mM MES pH 6.0,
20%(w/v) PEG 6000]. Optimization of these conditions was
carried out through variation of the precipitant concentrations
(8–22% PEG 1500 and PEG 6000), protein concentration
(5–10 mg ml1) and salt concentrations (100 and 200 mM).
Diffraction-quality crystals were obtained from an optimized
condition A8 from PACT premier [200 mM sodium chloride,
100 mM sodium acetate pH 5.0, 16%(w/v) PEG 6000] at a
protein concentration of 10 mg ml1 after incubation for 5–7 d
at 293 K.
The rTvTS1 crystals were cryocooled in liquid nitrogen with
the addition of 15%(v/v) glycerol to the mother liquor as a
cryoprotectant. A data set was collected from a single rTvTS1
crystal on the PROXIMA1 beamline at the SOLEIL
synchrotron, Gif-Sur-Yvette, France. 360 of data were
collected from the crystal in 0.2 slices using a Pilatus 6M
detector with an exposure time of 0.2 s per degree, a crystal-
to-detector distance of 392.60 mm and a wavelength of
0.98011 A˚. The collected data set was processed with XDS
(Kabsch, 2010) and the quality of the collected data set was
verified by close inspection of the XDS output files and by
using phenix.xtriage (Zwart et al., 2005) in the PHENIX
package (Adams et al., 2010). Twinning tests were performed
by phenix.xtriage. Analysis of the unit-cell contents was
performed with MATTHEWS_COEF, which is part of the
CCP4 package (Winn et al., 2011).
3. Results and discussion
An in silico BLAST search of the T. vivax Y486 genome
against the sequences of T. rangeli sialidase (UniProt code
O44049) and T. cruzi trans-sialidase (UniProt code Q26966)
resulted in the identification of five putative trans-sialidase
sequences, which will be referred to as TvTS1, TvTS2, TvTS3,
TvTS4 and TvTS5 (UniProt codes F9WU40, F9WQB0,
F9WQX6, G0TZP8 and F9WTR7, respectively) in the
following. As can be seen in Fig. 2 (top panel), these putative
TvTSs contain the conserved residues which are the hallmarks
of sialidases and trans-sialidases. In order to confirm the
presence of TvTS1–TvTS5 at the DNA and mRNA levels,
PCR was carried out on T. vivax lysates extracted from
infected mice blood. While this experiment confirmed the
existence of the TvTS genes in the genome, TvTS5 could not
be detected at the transcriptional level. The existence of the
remaining TvTSs at the protein level was checked by
screening the T. vivax lysates and the serum of infected mice
for sialidase/trans-sialidase activity. Given that the lysates and
infected serum samples scored positive for sialidase/trans-
sialidase activity in comparison to non-infected blood samples,
we reasoned that at least one TvTS manifested itself as an
active protein. Based on these results, TvTS1, TvTS3 and
TvTS4 were selected for recombinant production. TvTS2 was
omitted from this selection because of its high active-site
residue identity with TvTS3. Despite optimization efforts
during small-scale protein-production tests (different strains
and different additives), only recombinant TvTS1 (rTvTS1)
was produced in milligram quantities per litre of P. pastoris
culture. Nevertheless, the three proteins (rTvTS1, rTvTS3 and
rTvTS4) were purified by IMAC via their C-terminal hexa-
histidine tags in a small-scale purification setup. Only rTvTS1
was found to be a stable, soluble protein, while rTvTS3 and
rTvTS4 precipitated shortly after purification.
Large-scale protein production and purification was only
performed for rTvTS1. The enzyme was successfully produced
and secreted by P. pastoris cultures and can be obtained with
high purity using IMAC (Figs. 3a and 3b). After the purifica-
tion procedure, typical yields varied between 4 and 5 mg pure
protein per litre of P. pastoris culture. Interestingly, during
its production and purification the rTvTS1 protein does not
appear as a single band on SDS–PAGE. Instead, a pattern of
four distinct bands consistently appears, suggesting that the
protein could have been nicked or trimmed by proteases
during its production. In silico flexibility predictions indeed
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show that rTvTS1 most probably contains long loop regions
which could be vulnerable to proteolytic degradation (Fig. 2,
bottom panel). If rTvTS1 is proteolytically processed during
its production, this could have a significant influence on the
activity of the enzyme. Therefore, the purified (and possibly
truncated) rTvTS1 was tested in both sialidase and trans-
sialidase activity assays. From Fig. 3(c), it is clear that the
enzyme retains its trans-sialidase and residual sialidase activ-
ities. Because of its production in P. pastoris and the occur-
rence of nine potential glycosylation sites, rTvTS1 is expected
to be glycosylated. Because heterogeneity in the glycosylation
pattern of rTvTS1 could hamper crystallization, the enzyme
was deglycosylated by treatment with the endoglycosidase
enzyme EndoHf. A comparison via SDS–PAGE of rTvTS1
before and after EndoHf processing clearly demonstrates that
rTvTS1 was glycosylated during production in P. pastoris, as
the four-banded pattern now runs with a lower molecular mass
(Fig. 3b). While the residual sialidase activity of rTvTS1 is
moderately affected by the deglycosylation, the trans-sialidase
activity of the enzyme remains unaltered (Fig. 3c). Finally, to
assess the behaviour of deglycosylated rTvTS1 in solution,
analytical gel filtration was employed (Fig. 3d). The deglyco-
sylated protein elutes as a single peak at a position expected
for a globular protein of its size (an experimentally deter-
mined molecular mass of 93.9 kDa versus a theoretical mole-
cular mass of 97.6 kDa and an experimentally determined Rh
of 40.4 A˚ versus a theoretical Rh of 37.6 A˚). This again
strengthens the idea that loop regions of the protein are
probably proteolytically trimmed during its production,
without affecting its general three-dimensional structure and
molecular parasitology
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Figure 3
rTvTS1 is produced and purified as an active enzyme. (a) SDS–PAGE analysis of rTvTS1 production in P. pastoris. Lane 1, sample from the supernatant
of an induced culture. Lane M, Prestained Protein Molecular Weight Marker (Fermentas; labelled in kDa). (b) SDS–PAGE analysis of glycosylated
rTvTS1 purified via IMAC (lane 1). Deglycosylated rTvTS1 is shown in lane 2. Lane M, Prestained Protein Molecular Weight Marker (labelled in kDa).
(c) Trans-sialidase (left panel) and sialidase (right panel) activity assay performed with 25 pmol glycosylated (black) and deglycosylated (orange)
rTvTS1. (d) Analytical gel filtration. The experiment was performed on a Superdex 200 16/60 column. The orange and grey traces indicate the elution
profiles for deglycosylated rTvTS1 and the Bio-Rad standards (A, bovine thyroglobulin, molecular mass 670 kDa, Rh = 86.0 A˚; B, bovine -globulin,
molecular mass 158 kDa, Rh = 51.0 A˚; C, chicken ovalbumin, molecular mass 44 kDa, Rh = 28.0 A˚; D, horse myoglobin, molecular mass 17 kDa, Rh =
19.0 A˚; E, vitamin B12, molecular mass 1.35 kDa), respectively. The inset shows an SDS–PAGE analysis of the elution peak. Lane M, Prestained Protein
Molecular Weight Marker (labelled in kDa); the lanes marked with the asterisk are fractions from the deglycosylated rTvTS1 elution peak.
biochemical activity. This suspicion is confirmed by N-terminal
sequencing of the four distinct bands observed during SDS–
PAGE analysis. The N-terminal sequencing results demon-
strate that the proteolytic cuts are localized in parts of the
sequence which are expected to display increased flexibility
based on POODLE-L analysis (Hirose et al., 2007) or to be
loop regions based on sequence alignment (Fig. 2).
Having obtained high-quality preparations of enzymatically
active, deglycosylated rTvTS1, its crystallization was
attempted. Crystallization conditions were manually screened
by the sitting-drop vapour-diffusion method using various
commercial screens. Of the conditions screened, four
produced promising hits (the appearance of microcrystals)
after incubation for 7–14 d. All hits were from the PACT
premier screen: conditions A6 [100 mM SPG buffer pH 9.0,
25%(w/v) PEG 1500], A7 [200 mM sodium chloride, 100 mM
sodium acetate pH 5.0, 20%(w/v) PEG 6000], A8 [200 mM
ammonium chloride, 100 mM sodium acetate pH 5.0,
20%(w/v) PEG 6000] and B9 [200 mM lithium chloride,
100 mM MES pH 6.0, 20%(w/v) PEG 6000]. Optimization of
these conditions was carried out through variation of the
precipitant concentration (8–22% PEG 1500 and PEG 6000),
the protein concentration (5–10 mg ml1) and the concentra-
tion of the salts present (100 and 200 mM). Diffraction-quality
crystals were obtained using an optimized condition consisting
of 200 mM sodium chloride, 100 mM sodium acetate pH 5.0,
16%(w/v) PEG 6000 at a protein concentration of 10 mg ml1
after incubation for 5–7 d at 293 K (Fig. 4). To obtain single
crystals that could be used for X-ray diffraction experiments,
single needle crystals were dislodged from the crystal clusters
(Fig. 4) using a cryoloop. The single rTvTS1 crystals were
cryocooled in liquid nitrogen with the addition of 15%(v/v)
glycerol to the mother liquor as a cryoprotectant and
diffracted to a resolution of 2.5 A˚ (Fig. 4). The crystals
belonged to space group P212121, with unit-cell parameters a =
57.3, b = 78.4, c = 209.0 A˚, and contained one rTvTS1
monomer in the asymmetric unit according to Matthews
analysis (P = 1.0, 48.9% solvent content, VM = 2.41 A˚
3 Da1).
The resulting data-collection statistics are given in Table 1.
The elucidation of the crystal structure of rTvTS1 will be
interesting for several reasons. Firstly, the five newly identified
T. vivax trans-sialidases display low sequence identities to
other known trans-sialidases, including the well studied TcTS
enzyme from T. cruzi (Buschiazzo et al., 2012). While the
sequence identities between TvTS1 to TvTS5 range between
51 and 69%, the sequence identity of TvTS1 to other trypa-
nosomal (trans-)sialidases is much lower (between 19 and
32%). In addition, it seems that the TvTS enzymes, including
TvTS1, contain an extra 130 residues at the N-terminal
side of the trans-sialidase domain. The three-dimensional
molecular parasitology
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Table 1
Data-collection statistics for rTvTS1.
Values in parentheses are for the highest resolution shell.
Beamline PROXIMA1, SOLEIL
Wavelength (A˚) 0.98011
Resolution range (A˚) 44.26–2.48 (2.57–2.48)
Unit-cell parameters (A˚, ) a = 57.3, b = 78.4, c = 209.0,
 =  =  = 90
Space group P212121
Mosaicity () 0.247
Rmeas† 0.15 (1.0)
No. of measured reflections 439446 (37268)
No. of unique reflections 33882 (3105)
Multiplicity 12.9 (12.0)
hI/(I)i 14.721 (2.57)
Completeness (%) 99.32 (95.80)
† Rmeas =
P
hklfNðhklÞ=½NðhklÞ  1g1=2
P
i jIiðhklÞ  hIðhklÞij=
P
hkl
P
i IiðhklÞ (Dieder-
ichs & Karplus, 1997).
Figure 4
Morphology and diffraction of the rTvTS1 crystals. Top panel, rTvTS1
crystals obtained by the sitting-drop vapour-diffusion method (the
crystallization condition is described in the text) appear as clusters. The
black box displays an enlargement of the crystals. Bottom panel, a single
rTvTS1 crystal diffracted to a resolution of around 2.5 A˚ (the 2.5 A˚
resolution limit is indicated by an orange circle). The dashed box displays
an enlargement of the diffraction pattern.
architecture of this additional region as well as its function
remain enigmatic. It is tempting to speculate that the differ-
ences between the trans-sialidases encoded by intracellular
and extracellular trypanosomes might be related to the
distinct functions that these enzymes play in the divergent life
cycles of these two classes of parasite. Indeed, for the intra-
cellular trypanosome T. cruzi it has been shown that TcTS is
essential for host immune evasion and cell invasion by the
parasite (Lieke et al., 2011; Giorgi & de Lederkremer, 2011).
The biological role of TvTS1 is less well defined. Evidence
presented by Guegan et al. (2013) suggests that TvTS1 may
play a role in T. vivax-associated anaemia, although this
hypothesis requires further investigation. Study of the
structure–function relationship of TvTS1 will help in grasping
its biological function during bloodstream T. vivax parasite
infections and might serve as the basis for the development of
an antipathology treatment.
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